TENS Improves Cisplatin-Induced Neuropathy in Lung Cancer Patients.
TENS
cisplatin
cisplatin-induced neuropathy
lung cancer
neuropathic pain
neuropathy
quality of life
Journal
Medicina (Kaunas, Lithuania)
ISSN: 1648-9144
Titre abrégé: Medicina (Kaunas)
Pays: Switzerland
ID NLM: 9425208
Informations de publication
Date de publication:
06 Oct 2022
06 Oct 2022
Historique:
received:
31
07
2022
revised:
07
09
2022
accepted:
27
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Background: Cisplatin-induced peripheral neuropathy is a common complication of cisplatin therapy, which develops in most patients with lung cancer. There are no effective preventive measures and once it occurs there is no effective therapy, except symptomatic. In this study, we aimed to assess the effect of transcutaneous electrical nerve stimulation (TENS) therapy on the pain intensity and the quality of life of patients with cisplatin-induced neuropathy. Material and Methods: A prospective cohort study was performed from 2013 to 2018, at the Clinical Center of Serbia. After the initial evaluation of 106 newly diagnosed patients with lung cancer, 68 patients did not have peripheral neuropathy. These 68 patients continued in the study and started the cisplatin chemotherapy. Forty of these patients developed cisplatin-induced neuropathy, which was manifested by neuropathic symptoms and proven by ENG examination. All patients with cisplatin-induced neuropathy were treated with TENS therapy. Their neuropathic pain and quality of life were evaluated using the following questionnaires at diagnosis, after cisplatin therapy and after four weeks of TENS use: DN4, VAS scale, EORTC QLQ-C30 and FACT-L. Results: Two thirds (68%) of the patients with cisplatin-induced neuropathy were male and the majority were smokers (70%). Adenocarcinoma was the most common (38%), followed by squamous (33%) and small-cell carcinoma (28%). The application of TENS therapy had a positive effect on reducing the neuropathic pain and increasing the quality of life for patients with painful cisplatin-induced neuropathy. The VAS and DN4 scores significantly decreased after TENS therapy, in comparison to its values after cisplatin therapy (p < 0.001). After TENS therapy, patients had significantly higher values in most of the domains of EORTC QLQ-C30 and FACT- L, in comparison with the values after cisplatin therapy (p < 0.001). Conclusion: The application of TENS therapy has a positive effect on reducing neuropathic pain and increasing the quality of life for patients with lung cancer and cisplatin-induced neuropathy.
Identifiants
pubmed: 36295566
pii: medicina58101405
doi: 10.3390/medicina58101405
pmc: PMC9611034
pii:
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Clin J Pain. 2009 Jan;25(1):12-9
pubmed: 19158541
BMJ Open. 2017 Nov 12;7(11):e017307
pubmed: 29133320
Diabetes Care. 2000 Mar;23(3):365-70
pubmed: 10868867
Indian J Anaesth. 2010 Mar;54(2):116-20
pubmed: 20661348
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Diabetes Care. 1997 Nov;20(11):1702-5
pubmed: 9353612
Lung Cancer. 1995 Jun;12(3):199-220
pubmed: 7655830
Support Care Cancer. 2020 Nov;28(11):5323-5333
pubmed: 32128614
Thorac Cardiovasc Surg. 2007 Apr;55(3):182-5
pubmed: 17410506
Brain Behav. 2019 Jun;9(6):e01312
pubmed: 31063261
Cancer Treat Rev. 2014 Aug;40(7):872-82
pubmed: 24830939
J Hand Surg Br. 2005 Feb;30(1):50-5
pubmed: 15620492
J Neurol Neurosurg Psychiatry. 1999 Jul;67(1):7-14
pubmed: 10369814
Medicina (Kaunas). 2022 Feb 14;58(2):
pubmed: 35208610
Adv Exp Med Biol. 2013;756:333-9
pubmed: 22836651
World J Clin Oncol. 2014 Aug 10;5(3):197-223
pubmed: 25114839
Am J Phys Med Rehabil. 2004 Aug;83(8):584-91
pubmed: 15277959
CA Cancer J Clin. 2013 Nov-Dec;63(6):419-37
pubmed: 24590861
Health Technol Assess. 1997;1(6):i-iv, 1-135
pubmed: 9483161
Front Mol Neurosci. 2017 May 31;10:174
pubmed: 28620280
Clin J Oncol Nurs. 2010 Jun;14(3):E22-8
pubmed: 20529785
J Clin Oncol. 1992 May;10(5):795-803
pubmed: 1569451
Diagnostics (Basel). 2021 Mar 30;11(4):
pubmed: 33808121
Pain Physician. 2018 Nov;21(6):571-592
pubmed: 30508986
Eur J Cardiothorac Surg. 2012 Apr;41(4):861-8; discussion 868
pubmed: 22219414
J Biol Chem. 2017 Dec 15;292(50):20592-20598
pubmed: 28974579
Diabetes Nutr Metab. 2004 Jun;17(3):163-8
pubmed: 15334794
Pain. 2005 Mar;114(1-2):29-36
pubmed: 15733628
Rev Bras Anestesiol. 2011 Sep-Oct;61(5):561-7, 308-10
pubmed: 21920206
Brain. 2007 Apr;130(Pt 4):1076-88
pubmed: 17301082
Diabetologia. 2005 May;48(5):824-8
pubmed: 15830180
J Rehabil Med. 2014 May;46(5):454-60
pubmed: 24549206
Eur J Neurol. 2007 Sep;14(9):952-70
pubmed: 17718686
Neurology. 2010 Jan 12;74(2):173-6
pubmed: 20042705
Exp Neurol. 2014 May;255:137-44
pubmed: 24594220
Arch Phys Med Rehabil. 1977 Jan;58(1):8-13
pubmed: 299813
Eur J Cancer. 1994;30A(5):635-42
pubmed: 8080679
N Engl J Med. 2003 Mar 27;348(13):1223-32
pubmed: 12660386
J Natl Cancer Inst. 2009 Dec 16;101(24):1682-95
pubmed: 19940282
Neurosurgery. 2009 Feb;64(2):297-306; discussion 306-7
pubmed: 19057426
Semin Oncol. 2006 Feb;33(1):15-49
pubmed: 16473643
Lung Cancer. 2017 Sep;111:150-163
pubmed: 28838388
Curr Opin Neurol. 2015 Oct;28(5):500-7
pubmed: 26197027
Cancer. 1988 Jun 1;61(11):2192-5
pubmed: 2835140
World J Surg. 2005 Dec;29(12):1563-70
pubmed: 16331341
Br J Cancer. 2001 Sep 14;85(6):823-6
pubmed: 11556831
Eur J Neurol. 2010 Sep;17(9):1113-e88
pubmed: 20402746
Eur J Cancer. 2008 Jul;44(11):1507-15
pubmed: 18571399